XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) - Seite 2
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
Lesen Sie auch
As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except OJEMDA (tovorafenib), VABYSMO (faricimab-svoa), IXINITY [coagulation factor IX (recombinant)], DSUVIA (sufentanil sublingual tablet), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
XOMA Investor Contact | XOMA Media Contact |
Juliane Snowden | Kathy Vincent |
XOMA Corporation | KV Consulting & Management |
+1-646-438-9754 | +1-310-403-8951 |
juliane.snowden@xoma.com | kathy@kathyvincent.com |